Inhibikase Therapeutics Inc (IKT) saw an uptrend of 1.21% in the recent trading with $1.67 being its most recent. The current price level -49.70% lower than the highest price of $3.32 marked by the stock while trading over the past 52-weeks, whereas it is 25.56% higher than the lowest price of $1.33 the company dropped to over past 52-weeks. The latest news story on IKT appeared in (GlobeNewswire) under the title “Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants”.
Do analysts rate it as a buy, sell or hold?
Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Currently, the stock has been recommended as Strong Buy by 2 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 1.00 for the stock.
Inhibikase Therapeutics Inc Earnings – What Happened With IKT
Coming around sales and income figures on IKT Stock Income Statement, public trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor.
Inhibikase Therapeutics Inc – Insider Activity and Holdings
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 121.27 million. IKT does have institutional investors; and they hold 41.38% of the stock.
As on 2024-06-30, ARMISTICE CAPITAL, LLC was the top most holder in Inhibikase Therapeutics Inc (NASDAQ:IKT) with an ownership of 0.59 million shares of the company or 0.85 of the stake worth $0.71 million. The filing also reveals BLAIR WILLIAM & CO/IL as the second largest holder in the company with a control over 0.1674 of the outstanding shares. Its stake is worth $0.14 million for having 0.12 million shares in hand.
CITADEL ADVISORS LLC also came holding a key position in the company during the recent quarter and it now holds 0.0546 of the outstanding shares. With this there are now 81.0 institutions which have possession in IKT,s shares.
Key Metrics for IKT
The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. In recently reported quarter, Inhibikase Therapeutics Inc has a debt to equity ratio of 0.00.
